baber/WOPTO huggingface dataset:
Patent NZ-529205-A (NZ)
Title: Substituted azaindoles as inhibitors of protein kinases, and process for their preparation
Inventor: COX PAUL JOSEPH
IPC: A61P43/00
Filed: 2002-06-20
Abstract: Physiologically active substituted azaindole compounds of general formula (I): compositions containing such compounds; their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs are disclosed, wherein the variables shown in formula (I) are as defined in the specification. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases, whereby these compounds are suitable for use in the treatment of disease states capable of being modulated by the inhibition of the protein kinases.
Patent NZ-529279-A (NZ)
Title: Method of colorimetry and reagent for use therein
Inventor: NAGAKAWA KENJI
IPC: G01N33/52
Filed: 2003-01-06
Abstract: Disclosed is a colorimetric method including: transferring an electron from an analyte to a coloring reagent that produces color by reduction via a mediator by using an oxidoreductase; and performing qualitative or quantitative analysis of the analyte by measuring color produced in the coloring reagent; wherein the mediator is at least one selected from the group consisting of a copper complex, an iron complex, an osmium complex, and a ruthenium complex. Further disclosed are: 1) a reagent used for the colorimetric method according to claim 1, including: an oxidoreductase; a mediator; and a coloring reagent for producing color by reduction, wherein the mediator is at least one selected from the group consisting of a copper complex, an iron complex, an osmium complex, and a ruthenium complex; and 2) a test piece for colorimetric analysis which includes the reagent defined above.
Patent NZ-530545-A (NZ)
Title: Specific conjugates comprising a polypeptide exhibiting G-CSF activity and a non-polypeptide moiety
Inventor: NISSEN TORBEN LAUESGAARD
IPC: A61P31/00
Filed: 2002-07-10
Abstract: A polypeptide conjugate exhibiting G-CSF activity, comprising a polypeptide with an amino acid sequence that differs in 2-10 amino residues from the amino acid sequence of SEQ ID NO: 1. The polypeptide comprises at least one substitution selected from K16R/Q, K34R/Q and K40R/Q and at least one substitution selected from T105K and S159K relative to SEQ ID NO: 1. The conjugate has 2-6 polyethylene glycol moieties with a molecular weight of about 1000-10,000 Da attached to attachment groups of the polypeptide.
Patent NZ-537424-A (NZ)
Title: Orthotic kits and assemblies with contoured insole and pads and wedges
Inventor: BAYCROFT CHARLES MAXWELL
Filed: 2004-12-22
Abstract: An orthotic kit based on a new orthotic 'model' is disclosed which has a contoured insole, a wedge (17) for location under the lateral region of the fore foot region of the insole, and a wedge (18) for location under the medial region of the rear foot region of the insole. Typically there is also an inserted pad for each of a medial region of the forefoot and for a lateral region of the rear foot (13, 14). Typically, each wedge is at least as hard as the contoured insole.
Patent NZ-538777-A (NZ)
Title: Aluminium electrowinning cells with metal-based anodes having an oxide-based surface
Inventor: DE NORA VITTORIO
IPC: C25C3/18
Filed: 2003-10-17
Abstract: A cell for the electrowinning of aluminium is disclosed, which comprises a metal-based anode (10) containing at least one of nickel, cobalt and iron, for example an anode made from an alloy consisting of 50 to 60 weight% in total of nickel and/or cobalt; 25 to 40 weight% iron; 6 to 12 weight% copper; 0.5 to 2 weight% aluminium and/or niobium; and 0.5 to 1.5 weight% in total of further constituents. The anode (10) may have an applied hematite-based coating and optionally a cerium oxyfluoride-based outermost coating. The cell contains a fluoride-containing molten electrolyte (5) at a temperature below 940 DEG C, in which the anode is immersed and which consists of: 5 to 14 weight% dissolved alumina; 35 to 45 weight% aluminium fluoride; 30 to 45 weight% sodium fluoride; 5 to 20 weight% potassium fluoride; 0 to 5 weight% calcium fluoride; and 0 to 5 weight% in total of one or more further constituents. A nickel-containing anode stem (14b) can be used to suspend the anode (10) in the electrolyte facing a cathode (21,21A,25) that has an aluminium-wettable surface (20), in particular a drained horizontal or inclined surface.
Patent NZ-540891-A (NZ)
Title: 4-(2-Phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
Inventor: BANG-ANDERSEN BENNY
IPC: C07D211/70
Filed: 2004-04-02
Abstract: 4-(2-Phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives represented by the general formula (I) are disclosed, wherein the substituents are defined in the application. These compounds are suitable as serotonin reuptake inihibitors and are useful in the treatment of an affective disorder, including depression, anxiety disorders including general anxiety disorder and panic disorder and obsessive compulsive disorder.
Patent NZ-542438-A (NZ)
Title: Submerged power generating apparatus
Inventor: MANCHESTER JONATHAN RALPH
IPC: F03B13/10
Filed: 2004-02-26
Abstract: An undersea power generation apparatus (1) comprises two turbines (3) mounted side by side at either side of a support strut, each turbine (3) having a set of turbine blades which counter rotate. The apparatus (1) is pivotally interconnected at point (9) to a pair of mooring cables (7). The turbines (3) are positively buoyant such that in zero current they point vertically upwards. When the current flows in the direction shown by arrow A, the drag forces on turbines (3) and support strut cause the apparatus (1) to pivot about pivot point (9) and pitch over into the condition denoted by (10). When the tide begins to change direction, the magnitude of the water current flowing past the apparatus (1) decreases. Accordingly, the apparatus (1) will tend to float back into the vertical condition. Eventually, due to the effect of the tide, water will begin to flow in the direction shown by arrow B, and the apparatus (1) will pitch over into the position denoted by (12).
Patent NZ-544007-A (NZ)
Title: Highly plastic granules for making fast melting tablets
Inventor: FU YOURONG
IPC: A61K9/00
Filed: 2004-05-07
Abstract: Disclosed is a method of making a fast-melting tablet, comprising (a) combining a plastic substance and a water penetration enhancer to form an admixture thereof; (b) treating the admixture with an amount of a binder effective to form a mass of agglomerated particles thereof, wherein the binder is provided as an aqueous solution in a concentration range of20 to 85 wt%; (c) sieving and/or drying the agglomerated particles so as to isolate a plurality of highly plastic granules; and (d) compressing the highly plastic granules under low pressure to produce the fast melting tablet.
Patent NZ-550152-A (NZ)
Title: Microfluidized oil-in-water emulsions and vaccine compositions
Inventor: DOMINOWSKI PAUL JOSEPH
IPC: A61K39/39
Filed: 2005-03-24
Abstract: Disclosed is a vaccine comprising a saponin glycoside, a sterol and an antigen, wherein said saponin glycoside and said sterol associate with each other to form complexes in the form of helical micelles, and wherein said antigen is in admixture with, but not integrated within, said helical micelles.
Patent NZ-551283-A (NZ)
Title: Techniques for animating complex scenes
Inventor: GRASSIA FRANK SEBASTIAN
Filed: 2004-05-10
Abstract: A system for facilitating animation of a scene comprises a plurality of objects wherein the plurality of objects represented by a plurality of models is disclosed. The system comprises a processor; a volatile memory coupled to the processor and a storage subsystem coupled to the processor. The storage subsystem is configured to store instructions that when executed by the processor cause the processor to: receive information identifying a first model to be animated from the plurality of models; use a first representation to determine a set of models from the plurality of models that are needed for evaluation of the first model wherein the first representation comprising information identifying one or more inputs and outputs of the models in the plurality of models and identifying dependencies between the one or more inputs and outputs; and load the first model and the set of models in volatile memory, wherein the plurality of models comprises at least one model that is not loaded into the computer memory. The first representation is a graph comprising a plurality of nodes and links between the nodes and the nodes represent the inputs and the outputs of the plurality of models and the links represent the dependencies between the inputs and the outputs.
Patent NZ-551403-A (NZ)
Title: Formulations comprising a cephalosporin compound and their use treating bacterial infections in cats and dogs
Inventor: KIMBALL ROGER NELSON
Filed: 2002-11-13
Abstract: Disclosed is a method of treating or preventing a condition caused by a bacterial infection in dogs and cats comprising administering to the dog or cat a therapeutically effective amount of a compound of Formula I: wherein M+ is Na+, K+,or Li+ , effective in treating or preventing such a condition.
Patent NZ-552228-A (NZ)
Title: Retractable syringe with prevention of discharge until syringe is in extended position
Inventor: HARRISON NIGEL
IPC: A61M5/20
Filed: 2005-05-27
Abstract: An injection device 110, comprising a housing 112 adapted to receive a syringe 114 having a discharge nozzle, and a drive arranged on actuation to advance the syringe 114 from a retracted position to an extended position through an opening in the housing 112 and discharge the contents of the syringe 114, characterised by a locking mechanism which engages the drive with the syringe 114 when the syringe 114 is not in its extended position and which is disengaged from the drive and engages the syringe 114 with the housing 112 when the syringe 114 is in its extended position such that movement of the drive relative to the syringe 114 is prevented when the syringe 114 is advanced from its retracted position to its extended position and movement of the housing 112 relative to the syringe 114 is prevented when the syringe 114 is in its extended position and its contents are being discharged.
Patent NZ-552800-A (NZ)
Title: 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase Iepsilon
Inventor: METZ WILLIAM ARTHUR
IPC: A61K31/404
Filed: 2005-08-16
Abstract: Disclosed is an indole derivative of formula I or II, or a stereoisomer, enantiomer, racemate, tautomer, or pharmaceutically acceptable salt thereof, wherein X is S or SO, R2 is NR5R6, R3 is aryl or heterocycle, and wherein the other substituents are as defined in the specification. Also disclosed is a method of preparing the compound. Also disclosed is the an casein kinase Iepsilon inhibitor, such as the above compound for treating disorders of the central nervous system, such as mood disorders, sleep disorders, depression, bipolar disorder, shift work sleep disorder, jet lag syndrome, advanced sleep phase syndrome, and delayed sleep phase syndrome.
Patent NZ-555462-A (NZ)
Title: Cancer treatment method
Inventor: RUBIN STEPHEN
Filed: 2005-12-16
Abstract: Provided are compound N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methanesulphonyl) ethyl] amino } methyl)-2-furyl]-4-quinazolinamine and related compounds for the manufacture of medicaments to treat breast cancer that ha metastasized to the brain.
Patent NZ-555605-A (NZ)
Title: An arrangement for supporting a person or animal
Inventor: FUSCONE ROY
IPC: A47C23/26
Filed: 2005-10-26
Abstract: A bed 1 includes a peripheral frame 2, an anchor frame 3 below the peripheral frame, and a flexible membrane 11 stretched over and around the peripheral frame and tethered to the anchor frame by tethers 15 crossing diagonally beneath the membrane and anchored to the opposite side of the anchor frame. The support surface 14 of the membrane within the peripheral frame is permeable, and stretched sufficient tightly by the tethers to support a person. A structure (not shown) intermediate the peripheral and anchor frames prevents contact between the diagonally crossing tethers and the bottom surface of the membrane if a heavy person or animal lies on the bed.
Patent NZ-565253-A (NZ)
Title: Novel physiological substance nesfatin, substance relevant thereto, and use of the substances
Inventor: EGUCHI HIROSHI
IPC: A01K67/027
Filed: 2006-06-23
Abstract: Provided are specified peptides having an activity of suppressing food intake and/or suppressing body weight gain, as well as corresponding nucleic acid molecules and their variants. The peptides and nucleic acids can be used in therapy or screening/assaying of patients for predicting or diagnosing enhanced food intake or enhanced body weight gain, as well as for screening anti-obesity drugs.
Patent NZ-565719-A (NZ)
Title: Vertical-channel junction field-effect transistors with an epitaxial gate region on a drift layer
Inventor: CHENG LIN
IPC: H01L21/337
Filed: 2005-11-16
Abstract: Disclosed is a semiconductor device, such as a vertical-channel junction field-effect transistor. The device comprises: a substrate layer (1) comprising a semiconductor material of a first conductivity type; a drift layer (3) on the substrate layer; an epitaxial gate region (4) on the drift layer; a channel layer (7) covering a first portion of the gate region; and a source layer (9(a)) on the channel layer. The drift layer comprises a semiconductor material of the first conductivity type, the channel layer and source layer also being the first conductivity type. The gate region comprises a semiconductor material of a second conductivity type different than the first conductivity type. The source layer is deposited by epitaxial growth on the channel layer.
Patent NZ-569603-A (NZ)
Title: Method of making a protein hydrolysate using a cold incubation phase (10 degrees Celsius or less)
Inventor: BLANTON MADISON V
IPC: A23L13/00
Filed: 2007-01-04
Abstract: Disclosed is a method of making protein hydrolysates. The disclosed method comprises: (1) providing a solution comprising protein at a temperature of about 10 degrees Celsius or less; (2) adjusting a pH of the solution to an alkaline pH; and (3) adding a protease enzyme to the cooled, basic protein solution, wherein the protease enzyme converts at least a portion of the protein in the basic protein solution into protein hydrolysates at the temperature of about 10 degrees Celsius or less.
Patent NZ-573435-A (NZ)
Title: Recombinant vaccine against bluetongue virus
Inventor: Yao jian-sheng
IPC: C07K14/14
Filed: 2007-05-30
Abstract: Disclosed is an immunogenic composition comprising a recombinant pox virus that comprises one or more nucleic acid molecules encoding Bluetongue Virus VP2 and VP5. Also disclosed are methods for inducing an immunological or protective immune response using the immunogenic composition, methods for differential diagnosis using the immunogenic composition and kits including the composition.
Patent NZ-576425-A (NZ)
Title: Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
Inventor: AHMED GULZAR
IPC: C07D417/14
Filed: 2007-10-23
Abstract: Disclosed herein are fused bicyclic 2,4-diaminopyrimidine derivatives of formula I, wherein the substituents are as defined within the specification, processes for their preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as Anaplastic Lymphoma Kinase (ALK) and c-MET inhibitors and as such are useful in the treatment of proliferative disorders such as colon cancer, breast cancer, renal cancer, lung cancer, hemangioma, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, squamous cell carcinoma, myeloid leukaemia, melanoma, glioblastoma and astrocytoma.
Patent NZ-590356-A (NZ)
Title: Administration of the drug sumatriptan by iontophoresis
Inventor: SEBREE TERRI B
IPC: A61M31/00
Filed: 2008-10-30
Abstract: An iontophoretic patch designed to iontophoretically deliver sumatriptan using a current of about 4 mA or greater for at least a portion of a treatment period is disclosed, which is suitable for use in the treatment of a sumatriptan responsive state, wherein the sumatriptan responsive state is selected from migraine, familiar hemiplegic migraine with and without aura, chronic paroxysmal headache, cluster headache, migraine headache, basilar migraine and atypical headaches.
Patent NZ-598184-A (NZ)
Title: Composition for aqueous coating material and process for its production, and two-component curable aqueous coating material kit
Inventor: SUMI NAOKO
IPC: C09D5/00
Filed: 2007-04-25
Abstract: 598184 Disclosed is a process for producing a composition for aqueous coating material, which comprises: reacting a fluorinated copolymer (B) comprising from 40 to 60 mol percent of a structural unit of the formula (a1), from 3 to 50 mol percent of a structural unit of the formula (a2) and from 4.4 to 37 mol percent of a structural unit of the formula (a3) (provided that the total mol percent value of the respective structural units of the formulae (a1), (a2) and (a3) is from 80 to 100) with a dibasic acid anhydride in an organic solvent to esterify a part of the hydroxyl group in the structural unit of the formula (a3) to introduce a carboxyl group; adding a basic compound to neutralize at least a part of the carboxyl group with the basic compound; adding water; and removing the organic solvent to form the composition for aqueous coating material which comprises water, a synthetic resin dispersed or dissolved in the water, and which contains no organic solvent or an organic solvent in an amount of at most 3 mass percent based on the total mass of the composition for aqueous coating material, wherein the synthetic resin comprises a fluorinated copolymer (A) comprising from 40 to 60 mol percent of the structural unit of the formula (a1), from 3 to 50 mol percent of the structural unit of the formula (a2), from 4 to 30 mol percent of structural unit of the formula (a3) and 1.4 to 6 mol percent of a structural unit of the formula (a4) provided that the total mol percent value of the respective structural units of the formulae (a1), (a2), (a3) and (a4) is from 80 to 100.
Patent NZ-598666-A (NZ)
Title: Aqueous suspension concentrate formulations containing saflufenacil
Inventor: CANNAN TERRANCE M
IPC: A01P13/00
Filed: 2010-08-26
Abstract: 598666 Disclosed is an aqueous suspension concentrate formulation for plant protection, comprising the components: a) from 15 to 40 % by weight, based on the total weight of the formulation, 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)-pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)-amino]sulfonyl]benzamide (saflufenacil) in the form of its crystalline anhydrate; b) from 0.1 to 10 % by weight, based on the total weight of the formulation, at least one non-ionic surfactant selected from polyoxyethylene-polyoxy-C3-C4-alkylene blockcopolymers (such as Pluronic PE 10500); c) from 0.1 to 10 % by weight, based on the total weight of the formulation, at least one anionic surfactant comprising at least one arylsulfonate group (such as phenolsulfonic acid-formaldehyde polycondensate - Tamol DN); and d) from 40 to 84.8 % by weight, based on the total weight of the formulation, water. Further disclosed is a method of controlling undesired vegetation, comprising the application of the aqueous suspension concentrate formulation as defined above, in diluted or undiluted form, to plants, their environment and/or seeds.
Patent NZ-612837-A (NZ)
Title: A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson’s disease
Inventor: HOPP MICHAEL
IPC: A61K31/485
Filed: 2011-12-27
Abstract: The disclosure relates to the use of an opioid agonist or a pharmaceutically acceptable salt thereof and an opioid antagonist or a pharmaceutically acceptable salt thereof in the manufacture of an oral pharmaceutical dosage form to treat Parkinson’s disease and/or at least one symptom thereof, wherein the opioid agonist is selected from the group consisting of morphine, oxycodone, hydromorphone, dihydroetorphine, etorphine, nalbuphine, propoxyphene, nicomorphine, dihydrocodeine, diamorphine, papaveretum, codeine, ethylmorphine, phenylpiperidine, methadone, dextropropoxyphene, buprenorphine, pentazocin, tilidine, tramadol, tapentadol, hydrocodone and pharmaceutically acceptable salts thereof and the opioid antagonist is naloxone or a pharmaceutically acceptable salt thereof.
Patent NZ-621287-A (NZ)
Title: Murgantiol as a stink bug synergistic attractant for use outdoors
Inventor: SCHNEIDMILLER RODNEY G
IPC: A01P19/00
Filed: 2012-03-23
Abstract: Disclosed is a composition comprising the Harlequin bug pheromone, murgantiol, in a synergistic combination with at least one other stink bug attractant, such as methyl (2E,4E,6Z)-decatrienoate or methyl (2E,4Z)-decadienoate, or both, for attracting stink bugs such as the brown marmorated stink bug in outdoor settings. Stink bug traps comprising murgantiol, or synergistic compositions comprising murgantiol with at least one other stink bug attractant, and methods of using these compositions in traps outdoors are provided.
Patent NZ-625621-A (NZ)
Title: Treatment for diabetes in patients inappropriate for metformin therapy
Inventor: DUGI KLAUS
IPC: A61P3/10
Filed: 2009-08-05
Abstract: The disclosure relates to the use of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, which is a DPP-4 inhibitor, or a pharmaceutically acceptable salt thereof, for preparing a medicament for oral administration for treating and/or preventing of metabolic diseases in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin, wherein said DPP-4 inhibitor in the medicament is formulated for administration in an oral dose of 5 mg per day to said patients. Said medicament may be used in the treatment and/or prevention of type 2 diabetes mellitus in patients with at least one contraindication selected from: renal disease, renal impairment or renal dysfunction; dehydration; unstable or acute congestive heart failure; acute or chromic metabolic acidosis; and hereditary galactose intolerance. The disclosure also relates to the use of said DPP-4 inhibitor in combination with one or more further active substances selected from sulphonylureas, thiazolidinedones, glinides, alpha-glucosidase blockers, GLP-1 and GLP-1 analogues, and insulin and insulin analogues.